Lilly bags label extension for RET drug Retevmo in US Eli Lilly’s tissue-agnostic cancer drug Retevmo has just had its eligible patient population increased in the US. The Share X Lilly bags label extension for RET drug Retevmo in US https://pharmaphorum.com/news/lilly-bags-label-extension-for-ret-drug-retevmo-in-us/
First human data backs Calibr/AbbVie’s “switchable” CAR-T therapy California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which Share X First human data backs Calibr/AbbVie’s “switchable” CAR-T therapy https://pharmaphorum.com/news/first-human-data-backs-calibr-abbvies-switchable-car-t-therapy/
NICE says yes to BeiGene’s Brukinsa after Scottish nay BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine Share X NICE says yes to BeiGene’s Brukinsa after Scottish nay https://pharmaphorum.com/news/nice-says-yes-to-beigenes-brukinsa-after-scottish-nay/
Takeda farms out cancer drug alisertib to Puma Biotech Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed Share X Takeda farms out cancer drug alisertib to Puma Biotech https://pharmaphorum.com/news/takeda-farms-out-cancer-drug-alisertib-to-puma-biotech/
Opdivo set to take on Keytruda in adjuvant melanoma Bristol-Myers Squibb’s Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending Share X Opdivo set to take on Keytruda in adjuvant melanoma https://pharmaphorum.com/news/opdivo-set-to-take-on-keytruda-in-adjuvant-melanoma/
ESMO: Amgen reveals Lumakras data as rival looms in rear-view mirror Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the Share X ESMO: Amgen reveals Lumakras data as rival looms in rear-view mirror https://pharmaphorum.com/news/esmo-amgen-reveals-lumakras-data-as-rival-looms-in-rear-view-mirror/
ESMO: SpringWorks notches up a win in desmoid tumours Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported Share X ESMO: SpringWorks notches up a win in desmoid tumours https://pharmaphorum.com/news/esmo-springworks-notches-up-a-win-in-desmoid-tumours/
ESMO: Evidence builds for BioNTech’s amplified CAR-T therapy BioNTech has been thrust into the limelight with its mRNA-based vaccines and therapeutics – most notably its Pfizer-partnered Share X ESMO: Evidence builds for BioNTech’s amplified CAR-T therapy https://pharmaphorum.com/news/esmo-evidence-builds-for-biontechs-amplified-car-t-therapy/
ESMO: TIL therapy improves on Yervoy in melanoma trial A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at Share X ESMO: TIL therapy improves on Yervoy in melanoma trial https://pharmaphorum.com/news/esmo-til-therapy-improves-on-yervoy-in-melanoma-trial/
ESMO: Trodelvy’s overall survival benefit revealed Prospects for Gilead Sciences’ Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from Share X ESMO: Trodelvy’s overall survival benefit revealed https://pharmaphorum.com/news/esmo-trodelvys-overall-survival-benefit-revealed/
ESMO: Merck claims leap forward in head and neck cancer Germany’s Merck KGaA paid $237 million upfront for rights to Debiopharm’s head and neck squamous cell carcinoma (HNSCC) Share X ESMO: Merck claims leap forward in head and neck cancer https://pharmaphorum.com/news/esmo-merck-claims-leap-forward-in-head-and-neck-cancer/
Roche takes another punt on IL-2 in cancer with Good takeover Despite setbacks for projects trying to harness the power of the cytokine interleukin-2 (IL-2) as a cancer therapy, Share X Roche takes another punt on IL-2 in cancer with Good takeover https://pharmaphorum.com/news/roche-takes-a-punt-on-il-2-in-cancer-with-good-takeover/
Gilead claims first CAR-T approval for leukaemia in older adults Gilead Sciences’ Kite Pharma unit has carved out a niche for its CD19-targeted CAR-T therapy Tecartus in acute Share X Gilead claims first CAR-T approval for leukaemia in older adults https://pharmaphorum.com/news/gilead-claims-first-car-t-approval-for-leukaemia-in-older-adults/
Illumina eyeing future of Grail as EU shoots down merger The EU has blocked the merger of Illumina and Grail, saying the deal would stifle innovation in blood-based Share X Illumina eyeing future of Grail as EU shoots down merger https://pharmaphorum.com/news/illumina-eyeing-future-of-grail-as-eu-shoots-down-merger/
NICE says no to Lynparza in prostate cancer, creates UK access divide NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate Share X NICE says no to Lynparza in prostate cancer, creates UK access divide https://pharmaphorum.com/news/nice-says-no-to-lynparza-in-prostate-cancer-creating-uk-access-divide/
